Literature DB >> 11797175

Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications.

Roland Leclercq1.   

Abstract

Resistance to macrolides and lincosamides is increasingly reported in clinical isolates of gram-positive bacteria. The multiplicity of mechanisms of resistance, which include ribosomal modification, efflux of the antibiotic, and drug inactivation, results in a variety of phenotypes of resistance. There is controversy concerning the clinical relevance of in vitro macrolide resistance. Recent data, however, have shown that eradication of bacteria correlates with clinical outcome of acute otitis media in children and that macrolide therapy results in delayed eradication of macrolide-resistant pneumococci. These results support the need for in vitro detection of macrolide resistance and correct interpretation of susceptibility tests to guide therapy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11797175     DOI: 10.1086/324626

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  259 in total

1.  Phenotypic and molecular characterization of tetracycline- and erythromycin-resistant strains of Streptococcus pneumoniae.

Authors:  Maria P Montanari; Ileana Cochetti; Marina Mingoia; Pietro E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

2.  Antimicrobial susceptibilities of group B streptococci in New Zealand.

Authors:  Anja M Werno; Trevor P Anderson; David R Murdoch
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

3.  Quinupristin-dalfopristin resistance in Streptococcus pneumoniae: novel L22 ribosomal protein mutation in two clinical isolates from the SENTRY antimicrobial surveillance program.

Authors:  Ronald N Jones; David J Farrell; Ian Morrissey
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

4.  Antimicrobial susceptibilities of invasive pediatric Abiotrophia and Granulicatella isolates.

Authors:  Xiaotian Zheng; Alexandra F Freeman; Jay Villafranca; Dee Shortridge; Jill Beyer; William Kabat; Karen Dembkowski; Stanford T Shulman
Journal:  J Clin Microbiol       Date:  2004-09       Impact factor: 5.948

5.  Ribosomal mutations in Arcanobacterium pyogenes confer a unique spectrum of macrolide resistance.

Authors:  B Helen Jost; Hien T Trinh; J Glenn Songer; Stephen J Billington
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

Review 6.  Current concepts in laboratory testing to guide antimicrobial therapy.

Authors:  Stephen G Jenkins; Audrey N Schuetz
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

7.  ICESp2905, the erm(TR)-tet(O) element of Streptococcus pyogenes, is formed by two independent integrative and conjugative elements.

Authors:  Eleonora Giovanetti; Andrea Brenciani; Erika Tiberi; Alessandro Bacciaglia; Pietro Emanuele Varaldo
Journal:  Antimicrob Agents Chemother       Date:  2011-10-10       Impact factor: 5.191

8.  Fate of antimicrobial resistance genes in response to application of poultry and swine manure in simulated manure-soil microcosms and manure-pond microcosms.

Authors:  Mianzhi Wang; Yongxue Sun; Peng Liu; Jing Sun; Qin Zhou; Wenguang Xiong; Zhenling Zeng
Journal:  Environ Sci Pollut Res Int       Date:  2017-07-18       Impact factor: 4.223

9.  Failure of clindamycin to eradicate infection with beta-hemolytic streptococci inducibly resistant to clindamycin in an animal model and in human infections.

Authors:  James S Lewis; Alex J Lepak; George R Thompson; William A Craig; David R Andes; Kathryn E Sabol-Dzintars; James H Jorgensen
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

10.  Impact of community-associated, methicillin-resistant Staphylococcus aureus on management of the skin and soft tissue infections in children.

Authors:  Kanokporn Mongkolrattanothai; Robert S Daum
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.